Quintiles has a new name: Quintiles IMS Holdings Inc. – or QuintilesIMS – after the multi-billion-dollar merger between the two life science companies was officially wrapped up Monday morning.

Will there be any layoffs? That’s not clear at this point, but the companies said they expect $100 million in savings in three years.

However, the stock ticker for QuintilesIMS doesn’t change.

The combined company now trades under the symbol “Q” on the New York Stock Exchange.

Plans for the merger, valued at more than $17 billion, were announced in May.

The deal will have a major impact on Durham-based Quintiles’ management structure with executive and board changes.

A dual corporate headquarters is planned with operations in both Durham and New Jersey, where IMS is based.

“QuintilesIMS will maintain dual headquarters in Danbury, CT and Research Triangle Park with executives based in both locations,” Phil Bridges, Senior Director, Corporate Communications for QuintilesIMS, told WRAL TechWire.

“In addition, both Research Triangle Park and Danbury will house policy-making, governance and corporate/enterprise service functions.”

Whether there will be job cuts as a result of the merger isn’t clear at this point.

“While any large merger may impact some roles and responsibilities, we recognize the importance of our talented teams. Although, there may be some consolidation of certain functions our goal is to bring together the best of each company to deliver a truly differentiated experience for all of our stakeholders,” Bridges said.

“The merger is intended to accelerate growth in the combined company. The portfolios of the two companies are complementary and there is little overlap in the service portfolios. This merger is more about driving additive value rather than generating savings through subtraction. At the announcement of this merger in May, we estimated that annualized cost synergies of $100 million would be achieved by the end of the third year following the merger.”

Trading in IMS Holdings shares was halted. IMS recently raised $1.75 billion to help finance what the companies call a “merger of equals.” IMS shareholders will own a small majority of the stock.

Quintiles CEO Tom Pike takes on a lesser role in QuintilesIMS. Pike will serve as vice chairman and president for research and development solutions of the clinical research business.

Ari Bousbib, currently top executive at IMS, will serve as chairman and CEO of the combined company.

  • MORE COVERAGE: A management scorecard of combined company (WTW Insider)

Quintiles Chief Operating Officer Kevin Gordon has been expected to resign. Annie Lo and Leonard Schaeffer also gave up their Quintiles board seats.

  • VIDEO: Watch a video overview of the combined company at: https://youtu.be/sQlGY_bt2u4

The companies announced the finalization of the merger with little fanfare.

“The merger of IMS Health, a leading global information and technology services company, and Quintiles, the world’s largest provider of product development and integrated healthcare services, creates a leading information and tech-enabled healthcare service provider with global scale and reach, and a full suite of end-to-end clinical and commercial offerings,” Quintiles said in the announcement.

IMS shareholders received 0.3840 of a share of Quintiles stock in exchange for their IMS shares.

Combined, QuintilesIMS employs some 50,000 people across more than 100 countries.